Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026Score 7/30

$33.98+0.05 (+0.15%)

Close on Nov 13, 2026Market cap $2.24BP/E 6.3Yield –

Lakefront Biotherapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Lakefront Biotherapeutics's EV/EBITDA was 6.4× on Nov 11, 2026, against 9.3× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	6.4×	+1.7
2021	Feb 26, 2021	4.7×	−1.3
2020	Dec 31, 2020	6.0×	–

Parsed from the XBRL in Lakefront Biotherapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LKFT.

Revenue growth303.5% · median 59.5%

Gross margin97.3% · median 83.6%

Operating margin26.5% · median 12.8%

Net margin28.9% · median 1.2%

Advertisement
300 × 250

See a number that looks wrong?